Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 21, 2001 - Issue 4
Submit an article Journal homepage
13
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Cardiovascular oestrogen effects in women

G. Finking, May Hussein Gohar, Christina Lenz, H. Hanke Department of Internal Medicine, Division of Cardiology, University of Ulm, Germany
Pages 340-349 | Published online: 02 Jul 2009

  • Abu-Halawa S.A., Thompson K., Kirkeeide R.L., Vaughn W.K., Resales O., Fujisi K., Schroth G., Smalling R. and Anderson H.V. (1998) Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. American Journal of Cardiology, 82, 409-413.
  • Adams M.R., Register T.C., Golden D.L., Wagner J.D. and Williams J.K. (1997) Medroxyprogesterone acetate antagonises inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology, 17, 217-221.
  • Adams M.R., Williams J.K., Clarkson T.B. and Jayo M.J. (1991) Effects of oestrogens and progesterone on coronary atherosclerosis and osteoporosis of monkeys. Baillière's Clinical Obstetrics and Gynaecology, 5, 915-934.
  • Barrett-Connor E. (1997) The sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation, 95, 252-264.
  • Barrett-Connor E. and Bush T.L. (1991) Estrogen and coronary heart disease in women. Journal of the American Medical Association, 265, 1861-1867.
  • Bath P.M., Hassall D.G., Gladwin A.M., Palmer R.M. and Martin J.F. (1991) Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arteriosclerosis and Thrombosis, 11, 254-260.
  • Berkson D.M., Stamler J. and Cohen D.B. (1964) Ovarian function and coronary atherosclerosis. Clinical Obstetrics and Gynecology, 7, 504-530.
  • Bhakdi S. (1998) An alternative hypothesis of the pathogenesis of atherosclerosis. Herz, 23, 163-167.
  • Blumenthal R.S., Brinker J.A., Resar J.R., Gloth S.T., Zacur H.A., Coombs V., Gerstenblith G. and Reis S.E. (1997b) Long-term estrogen therapy abolishes acute estrogen-induced coronary flow augmentation in postmenopausal women. American Heart Journal, 133, 323-328.
  • Blumenthal R.S., Heldman A.W., Brinker J.A., Resar J.R., Coombs V.J., Gloth S.T., Gerstenblith G. and Reis S.E. (1997a) Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in men. American Journal of CardioIogy, 80, 1021-1024.
  • Brehme U., Brack B., Gugel N., Wehrmann M., Hanke S., Finking G, Schmahl F.W. and Hanke H. (1999) Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous or sequential progestin. Anteriosclerosis, Thrombosis and Vascular Biology, 19, 19301937.
  • Buja L.M., Kita T., Goldstein J.L., Watanabe Y. and Brown M.S. (1983) Cellular pathology of progressive atherosclerosis in the WHHL rabbit, an animal model of familial hypercholesterolemia. Arteriosclerosis, 3, 87-101.
  • Bush T.L. and Barrett-Connor E. (1985) Noncontraceptive estrogen use and cardiovascular disease. Epidemiologic Reviews, 7, 80-104.
  • Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., Suchindran C.M.,Tyroler H.A. and Rifkind B.M. (1987) Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation, 75, 1102-1109.
  • Chandrasekar B. and Tanguay J.F. (2000) Local delivery of 17bestradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model. Journal of the American College of Cardiology, 36, 1972-1978.
  • Chen S.-J., Li H., Durand J., Oparil S. and Chen Y.-F. (1996) Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation, 93, 577-584.
  • Chen Z., Yuhanna I.S., Galcheva-Gargova Z.I., Karas R.H., Mendelsohn M.E. and Shaul PW. (1999) Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. Journal of Clinical Investigation, 103, 401-406.
  • Collins P., Beale C.M. and Rosano GM. (1996) Oestrogen as a calcium channel blocker. European Heart Journal, 17(Suppl D), 27-31.
  • Collins P., Rosano G.M.C., Sarrel P.M., Ulrich L., Adamopoulos S., Beale C.M., McNeill J.G. and Poole-Wilson P.A. (1995) 17b-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation, 92, 24-30.
  • Cornwell T.L., Arnold E., Boerth NJ. and Lincoln T.M. (1994) Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. American Journal of Physiology, 267, C1405-C1413.
  • Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., Sakkinen P.A. and Tracy R.P. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation, 100, 717-722.
  • Dubey R.K., Gillespie D.G, Imthurn B., Rosselli M., Jackson E.K. and Keller P.J. (1999) Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension, 33, 177-182.
  • Eriksson M., Berglund L., Rudling M., Henriksson P. and Angelin B. (1989) Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma. Journal of Clinical Investigation, 84, 802-810.
  • Finking G, Hess B. and Hanke H. (1999) The value of phytoestrogens as a possible therapeutic option in postmenopausal women with coronary heart disease. Journal of Obstetrics and Gynaecology, 19, 455-459.
  • Fröhlich M., Schunkert H., Hense H.-W., Tropitzsch A., Hendricks P., During A., Riegger G.A. and Koenig W. (1998) Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. British Journal ofHaematology, 100, 577-581.
  • Fuster V., Badimon L., Badimon J.J. and Chesebro J.H. (1992a) The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). New England Journal of Medicine, 326, 242-250.
  • Fuster V., Badimon L., Badimon J.J. and Chesebro J.H. (1992b) The pathogenesis of coronary artery disease and the acute coronary syndromes (second of two parts). New England Journal of Medicine, 326, 310-318.
  • Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A. and Cannon III R.O. ( 1994b) Acute vascular effects of estrogen in postmenopausal women. Circulation, 90, 786-791.
  • Gilligan D.M., Quyyumi A.A. and Cannon R.O. (1994a) Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation, 89, 25452551.
  • Glomset J.A. (1968) The plasma lecithin: cholesterol acyltransferase reaction. Journal of Lipid Research, 9, 155-167.
  • Glueck C.J., Wang P., Fontaine R.N., Trent T., Sieve-Smith L. and Lang J.E. (1999) The thrombophilic Factor V Leiden mutation (resistance to activated Protein C) and estrogen replacement therapy as risk factors for atherothrombotic cardiovascular disease in 423 hyperlipidemic women. Circulation, 100, 1-331 [Abstract].
  • Grodstein F., Stampfer M.J., Colditz GA., Willett W.C., Manson J.E., Joffe M., Rosner B., Fuchs C., Hankinson S.E., Hunter DJ., Hennekens C.H. and Speizer F.E. (1997) Postmenopausal hormone therapy and mortality. New England Journal of Medicine, 336, 1769-1775.
  • Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., Speizer P.E. and Hennekens C.H. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine, 335, 453-461.
  • Grohe C., Kahlert S., Lobbert K., Stimpel M., Karas R.H., Vetter H. and Neyses L. (1997) Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Letters, 416, 107-112.
  • Grohe C., Kahlert S., Lobbert K. and Vetter H. (1998) Expression of estrogen receptor alpha and beta in rat heart role of local estrogen synthesis: Journal of Endocrinology, 156, R1-7.
  • Gustafsson J.-A. (1997) Estrogen receptor ß-getting in on the action. Recent findings in mice hint that ERb and not ERa mediate some of the vascular benefits of estrogen. Nature Medicine, 3, 493-494.
  • Han S.Z., Karaki H., Ouchi Y., Akishita M. and Orimo H. (1995) 17b-estadiol inhibits Ca2+ influx and Ca2+ release induced by thromboxane A2 in porcine coronary artery. Circulation, 91, 2619-2626.
  • Hanke H., Hanke S., Brack B., Brehme U., Gugel N., Finking G, Muck A.O., Schmahl F.W., Hombach V. and Haasis R. (1996) Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis, 121, 129138.
  • Hanke H., Hanke S., Ickrath O., Lange K., Brack B., Muck A.O., Seeger H., Zwirner M., Voisard R., Haasis R. and Hombach V. (1997) Estradiol concentrations in premenopausal women with coronary heart disease. Coronary Artery Disease, 8, 511-515.
  • Hanke H., Kamenz J., Hanke S., Spieb J., Lenz C., Brehme U., Brack B., Finking G. and Hombach V. (1999) Effect of 17ß-estradiol on pre-existing atherosclerotic lesions: role of the endothelium. Atherosclerosis, 147, 123-132.
  • Hayashi T., Fukuto J.M., Ignarro L.J. and Chaudhuri G. (1992) Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proceedings of the National Academy of Sciences USA, 89, 11259-11263.
  • Hennekens C.H., Evans D. and Peto R. (1979) Oral contraceptive use, cigarette smoking, and myocardial infarction. British Journal of Family Planning, 5, 66-67.
  • Henry P.D. and Bentley K.I. (1981) Suppression of atherogensis in cholesterol-fed rabbits treated with nifedipine. Journal of Clinical Investigation, 68, 1366-1369.
  • Hernandez-Avila M., Walker A.M. and Jick H. (1990) Use of replacement estrogens and the risk of myocardial infarction. Epidemiology, 1, 128-133.
  • Ho Y., Brown M.S. and Goldstein J.L. (1980) Hydrolysis and excretion of cytoplasmic cholesterylesters by macrophages: stimulation by high density lipoproteins and other agents. Journal of Lipid Research, 21, 319-398.
  • Hodges Y.K., Tung L., Yan X.-D., Graham J.D., Horwitz K.B. and Horwitz L.D. (2000) Estrogen receptor a and ß. Prevalence of estrogen receptor ß mRNA in human vascular smooth muscle and transcriptional effects. Circulation, 101, 1792-1798. http:www.scs.uiuc.edu/-hapiro/
  • Hulka B.S., Kaufman D.G., Fowler W.C., Crimson R.C. and Greenberg B.G. (1980) Predominance of early endometrial cancers after long-term estrogen use. Journal of the American Medical Association, 244, 2419-2422.
  • Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. and Vittinghoff E. (1998) Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association, 280, 605-613.
  • Iafrati M.D., Karas R.H., Aronovitz M., Kim S., Sullivan T.R., Lubahn D.B., O'Donnell T.F., Korach K.S. and Mendelsohn M.E. (1997) Estrogen inhibits the vascular injury response in receptor a-deficient mice. Nature Medicine, 3, 545-548.
  • Isner J.M., Kearney M., Bortman S. and Passeri J. (1995) Apoptosis in human atherosclerosis and restenosis. Circulation, 91, 2703-2711.
  • Jiang C., Poole-Wilson P.A., Sarrel P.M., Mochizuki S., Collins P. and MacLeod K.T. (1992) Effect of 17ß-oestradiol on contraction, Ca-2+ current and intracellular free Ca-2+ in guinea-pig isolated cardiac myocytes. British Journal of Pharmacology, 106, 739-745.
  • Jiang C., Sarrel P.M., Lindsay D.C., Poole-Wilson P.A. and Collins P. (1991) Endothelium-independent relaxation of rabbit coronary artery by 17b-oestradiol in vitro. British Journal of Pharmacology, 104, 1033-1037.
  • Kannel B.W., Hjortland M.C., McNamara P.M. and Gordon T. (1976) Menopause and risk of cardiovascular disease. The Framingham Study. Annals of Internal Medicine, 85, 447-452.
  • Karas R.H., Hodgin J.B., Kwoun M., Krege J.H., Aronovitz M., Mackey W., Gustafsson J. A., Korach K.S., Smithies O. and Mendelsohn M.E. (1999) Estrogen inhibits the vascular injury response in estrogen receptor ß-deficient female mice. Proceedings of the National Academy of Sciences USA, 96, 15133-15136.
  • Karas R.H., Patterson B.L. and Mendelsohn M.E. (1994) Human vascular smooth muscle cells contain functional estrogen receptor. Circulation, 89, 1943-1950.
  • Klouche M., May A.E., Hemmes M., Messner M., Kanse S.M., Preissner K.T. and Bhakdi S. (1999) Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers. Arteriosclerosis, Thrombosis and Vascular Biology, 19, 784-793.
  • Koenig W. (1998) Haemostatic risk factors for cardiovascular diseases. European Heart Journal, 19(Suppl.), C39-C43.
  • Krasinski K., Spyridopoulos I., A Sahara T., van der Zee R., Isner J.M. and Losordo D.W. (1997) Estradiol accelerates functional endothelial recovery after arterial injury. Circulation, 95, 1768-1772.
  • Krueger P.M. (2000) Clinical use of selective estrogen receptor modulators. Journal of the American Osteopathic Association, 100(Suppl.), S6-S8.
  • Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S. and Gustafsson J.A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and ß. Endocrinology, 138, 863-870.
  • Kuiper G.G.J.M., Enmark E., Pelto-Huikko M., Nilsson S. and Gustafsson J.A. (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences USA, 93, 5925-5930.
  • Levi M., Middeldorp S. and Büller H.R. (1999) Oral contraceptives and hormonal replacement therapy cause an imbalance in coagulation and fibrinolysis which may explain the increased risk of venous thromboembolism. Cardiovascular Research, 41, 21-24.
  • Lin A.L., Gonzalez R., Carey K.D. and Shain S.A. (1986) Estradiol-17-beta affects estrogen receptor distribution and elevates progesterone receptor content in baboon aorta. Arteriosclerosis, 6, 495-504.
  • Lin A.L., McGiIl H.C. and Shain S.A. (1982) Hormone receptors of the baboon cardiovascular system. Circulation Research, 50, 610-616.
  • Lindner V., Kim S.K., Karas R.K., Kuiper G.G.J.M., Gustafsson J.-A. and Mendelsohn E. (1998) Increased expression of estrogen receptor-b mRNA in male blood vessels after vascular injury. Circulation Research, 83, 224-229.
  • Loch E.-G (1998) Hormonbehandlung des alternden Menschen; 22. Interdisziplinäres Forum der Bundesärztekammer 'Fortschritt und Fortbildung in der Medizin' vom 28. bis 31. Januar 1998. Deutsches Ärzteblatt, 95, C859-C861.
  • Losordo D.W., Kearney M., Kim E.A., Jekanowski J. and Isner J.M. (1994) Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation, 89, 1501-1510.
  • Ludden J.B., Bruger M. and Wright I.S. (1942) Experimental atherosclerosis; effect of testosterone propionate and estradiol dipropionate on experimental atherosclerosis in rabbits. Archives of Pathology, 33, 58-62.
  • Mäkelä S., Savolainen H., Aavik E., Myllärniemi M., Strauss L., Taskinen E., Gustafsson J.-A. and Häyry P. (1999) Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors a and ß. Proceedings of the National Academy of Sciences USA, 96, 7077-7082.
  • Master A., Dack S. and Jaffe H.L. (1939) Age, sex and hypertension in myocardial infarction due to coronary occlusion. Archives of Internal Medicine, 64, 767-786.
  • Mendelsohn M.E. and Karas R.H. (1999) The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine, 340, 1801-1811.
  • Mosselman S., Polman J. and Dijkema R. (1996) ER-ß: identification and characterisation of a novel human estrogen receptor. FEBS Letters, 392, 49-53.
  • Muck A.O., Seeger H., Korte K. and Lippert T.H. (1993) The effect of 17ß-estradiol and endothelin-1 on prostacyclin and thromboxane production in human endothelial cell cultures. Clinical and Experimental Obstetrics and Gynecology, 20, 203-206.
  • Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G, Wu K.K. and Szklo M. (1993) Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. New England Journal of Medicine, 328, 1069-1075.
  • Nickening G., Baumer A.T., Grobe C., Kahlert S., Strehlow K., Rosenkranz S., Stablein A., Beckers F., Smits J.F., Daemen M.J., Vetter H. and Bohm M. (1998) Estrogen modulates AT-1 receptor gene expression in vitro and in vivo. Circulation, 97, 2197-2201.
  • O'Brien I.E., Peterson E.D., Keeler GP., Berdan L.G, Ohman E.M., Faxon D.P., Jacobs A.K., Topol E.J. and Califf R.M. (1996) Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. Journal of the American College of Cardiology, 28, 1111-1118.
  • O'Keefe J.H., Kim S.C., Hall R.R., Cochran V.C., Lawthorn S.L. and McCallistar B.D. (1997) Estrogen replacement therapy after coronary angioplasty in women. Journal of the American College of Cardiology, 29, 1-5.
  • Oparil S. (1999) Hormones and vasoprotection. Hypertension, 33, 170-176.
  • Oparil S., Chen S.-J., Chen Y.-K, Durand J.N., Allen L. and Thompson J. A. (1999) Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. Cardiovasccular Research, 44, 608-614.
  • Paech K., Webb P., Kuiper G.G.J.M., Nilsson S., Gustafsson J.-A., Kushner P.J. and Scanlan T.S. (1997) Differential ligand activation of estrogen receptors ERa and ERß at AP1 sites. Science, 277, 1508-1510.
  • Parini P., Angelin B. and Rudling M. (1997) Importance of estrogen receptors in hepatic LDL receptor regulation. Arteriosclerosis, Thrombosis and Vascular Biology, 17, 1800-1805.
  • Patrick T.S., Yamamoto T., Goldstein J.L. and Brown M.S. (1986) Increased mRNA for a low density lipoprotein receptor in livers treated with 17a-ethinyl estradiol. Proceedings of the National Academy of Sciences USA, 83, 792-796.
  • Pennisi E. (1997) Differing roles found for estrogen's two receptors. Science, 277, 1439-1440.
  • Proudler A J., Ahmed A.I., Crook D., Fogelman I., Rymer J.M. and Stevenson J.C. (1995) Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet, 346, 89-90.
  • Radomski M.W., Palmer R.M. and Moncada S. (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 2, 1057-1058.
  • Register T.C. and Adams M.R. (1998) Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. Journal of Steroid Biochemistry and Molecular Biology, 64, 187-191.
  • Reis S.E., Cloth S.T., Blumenthal R.S., Resar J.R., Zacur H.A., Gerstenblith G and Brinker J.A. (1994) Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation, 89, 52-60.
  • Rich-Edwards J.W., Manson I.E., Hennekens C.H. and During I.E. (1995) The primary prevention of coronary heart disease in women. New England Journal of Medicine, 332, 1758-1766.
  • Ridker P.M., Hennekens C.H., Rifai N., Buring I.E. and Manson I.E. (1999) Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation, 100, 713-716.
  • Riedel M., Rafflenbeul W. and Lichtlen P. (1993) Ovarian sex steroids and atherosclerosis. Clinical Investigation, 71, 406-412.
  • Rifici VA. and Khachadurian A.K. (1992) The inhibition of low-density lipoprotein oxidation by 17ß-estradiol. Metabolism, 41, 1110-1114.
  • Rosano G.M., Peters N.S., Lefroy D., Lindsay D.C., Sarrel P.M., Collins P. and Poole- Wilson PA. (1996) 17ß-Esradiol therapy lessens angina in postmenopausal women with syndrome X. Journal of the American College of Cardiology, 28, 15001505.
  • Ross R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809.
  • Sack M.N., Rader D.J. and Cannon III RO. (1994) Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet, 343, 269-270.
  • Salomaa V., Rasi V., Pekkanen J., Vahtera E., Jauhiainen M., Vartiainen E., Ehnholm C., Tuomilehto J. and Myllyla G. (1995) Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK Haemostasis Study. Arteriosclerosis, Thrombosis and Vascular Biology, 15, 1549-1555.
  • Sanders M. (1994) Molecular and cellular concepts in atherosclerosis. Journal of Pharmacology and Therapentics, 61, 109-153.
  • Sartwell P.E., Masi A.T., Arhes F.D.G., Green GR. and Smith H.E. (1969) Thromboembolism and oral contraceptives: an epidemiologic case-control study. American Journal of Epidemiology, 90, 365-380.
  • Sattar N., Greer I.A., Rumley A., Steward G, Shepherd J., Packard C.J. and Lowe GD. (1999) A longitudinal study of the relationships between haemostatic, lipid, and oestnadiol changes during normal human pregnancy. Thrombosis and Haemostasis, 81, 71-75.
  • Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Alba Y., Tanaka T., Miwa S., Katsura Y., Kita T. and Masaki T. (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature, 386, 73-77.
  • Schunkert H., Danser A.H.J., Hense H.W., Derkx F.H., Kurzinger S. and Riegger GA. (1997) Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation, 95, 39-45.
  • Shiomi M., Ito T. and Watanabe Y. (1987) Increase in hepatic low-density lipoprotein receptor activity during pregnancy in Watanabe heritable hyperlipemic rabbits; an animal model for familial hypercholesterolemia. Biochimica et Biophysica Acta, 917, 92-100.
  • Spyridopoulos I., Sullivan A.B., Kearney M., Isner J.M. and Losordo D.W. (1997) Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation, 95, 1505-1514.
  • Stadel B.V. (1981) Oral contraceptives and cardiovascular disease. New England Journal of Medicine, 305, 672-677.
  • Stampfer M.J., Colditz GA., Willett W.C., Manson J.E., Rosner B., Speizer F.E. and Hennekens C.H. (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. New England Journal of Medicine, 11, 756-762.
  • Steinberg D., Parthasarathy S., Carew T., Khoo J.C. and Witztum J.L. (1989) Beyond cholesterol. Modifications of LDL that increase its atherogenicity. New England Journal, 320, 915-924.
  • Steinbrecher U.R. Zhang H., Lougheed M. (1990) Role of oxidatively modified LDL in atherosclerosis. Free Radical Biology and Medicine, 9, 155-168.
  • Sullivan J.M., van der Zwag R., Hughes J.R, Maddock V., Kroetz F.W., Ramanathan K.B. and Mirvis D.M. (1990) Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Archives of Internal Medicine, 150, 2557-2562.
  • Sullivan J.M., Zwaag R.V., Lemp GR, Hughes J.R, Maddock V., Kroetz F.W., Ramanathan K.B. and Mirvis D.M. (1988) Postmenopausal estrogen use and coronary atherosclerosis. Annals of Internal Medicine, 108, 358-363.
  • Suzuki A., Mizuno K., Ino Y., Okada M., Kikkawa F., Mizutani S. and Tomoda Y. (1996) Effects of 17ß-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Cardiovascular Research, 32, 516-523.
  • The Writing Group for the Estradiol Clotting Factors Study (1996) Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a one year, double blind, placebo-controlled study. Thrombosis and Haemostasis, 75, 476-480.
  • The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/ progestin interventions (PEPI) trial. Journal of the American Medical Association, 273, 199-208.
  • Tikkanen M.J. (1990) Role of lipoproteins in the pathogenesis of atherosclerotic disease, with special reference to sex hormone effects. American Journal of Obstetrics and Gynecology, 163, 296-304.
  • Vargas R., Wroblewska B., Rego A., Hatch J. and Ramwell P.W. (1993) Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. British Journal of Pharmacology, 109, 612-617.
  • Venkov C.D., Rankin A.B., Vaughan D.E. (1996) Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation, 94, 727-733.
  • Vessey M.P., Mant D., Smith A. and Yeates D. (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. British Medical Journal, 292, 526.
  • Walsh B.W., Schiff L, Rosner B., Greenberg L., Ravnikar V. and Sacks F.M. (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine, 325, 1196-1204.
  • Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Bergstrom R., Lindgren A., Correia N. and Persson I. (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute, 91, 1131-1137.
  • Williams J.K., Adams M.R. and Klopfstein H.S. (1990) Estrogen modulates responses of atherosclerotic coronary arteries. Circulation, 81, 1680-1687.
  • Wilson P.W.F., Garrison R.J. and Castelli W.P. (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. New England Journal of Medicine, 313, 1038-1043.
  • Witztum J.L. (1994) The oxidation hypothesis of atherosclerosis. Lancet, 344, 793-795.
  • Ylikorkala O., Orpana A., Puolakka J., Pyorala T. and Viinikka L. (1995) Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. Journal of Clinical Endocrinology and Metabolism, 80, 3384-3387.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.